“Three Russian peptides, one American marketing term. Here’s what the data actually shows.”
Regulatory Status
Current Status — April 2026
None of the three compounds are FDA-approved in the United States. All three are approved for clinical use in Russia — Semax for acute ischemic stroke (1994), Selank for generalized anxiety disorder (2009), and Epitalon / Epithalamin within the Khavinson pineal-peptide clinical programs.
In the US, some 503A compounding pharmacies compound Selank and Semax under prescription via telehealth channels. Epitalon is primarily sourced from research peptide vendors; US pharmacy compounding access for Epitalon is more limited and varies by pharmacy. The "Flow State" combination itself has no regulatory status as a combination product — it is a community-assembled stack of three individual compounds.
None of the three are on the 2025 WADA Prohibited List as individually named substances. Athletes should confirm sport-federation rules independently; novel-peptide provisions can apply.
The Three Components
Flow State is the sum of three separate compounds. Each has its own mechanism, its own evidence base, and its own community. The stack's premise is that the three layers — calm, focus, sleep — are non-overlapping. Here's what each compound actually is.
- What it is — Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-amino-acid synthetic analog of the immune peptide tuftsin (a short peptide fragment that modulates immune cells). Approved in Russia in 2009 for generalized anxiety disorder and asthenic-neurasthenic conditions.
- Documented effects — Anxiolytic (anti-anxiety) without benzodiazepine-like sedation, mild nootropic (cognitive-supporting) effect on attention and working memory, and peripheral immune modulation through the tuftsin pathway.
- Primary mechanism — Modulation of the GABAergic (the brain's primary calming transmitter system) gene expression, BDNF elevation (brain-derived neurotrophic factor — the growth signal that keeps neurons healthy), and enkephalinase inhibition.
- Community intranasal dose in Flow State — 200–400 mcg per day, split across nostrils. Daily dosing for 2–3 week cycles is the most-reported pattern.
- Half-life — Short (measured in minutes to hours); multiple daily doses are typical.
MEHFPGP · ACTH(4-7) + PGP
- What it is — Met-Glu-His-Phe-Pro-Gly-Pro, a heptapeptide (a chain of seven amino acids) modeled on the ACTH(4-7) fragment with a C-terminal PGP extension for stability. Approved in Russia in 1994 for acute ischemic stroke and related neurological indications.
- Documented effects — Neuroprotection in ischemic stroke (Russian pivotal trial), BDNF upregulation within hours of intranasal dosing, and cognitive enhancement on attention, working memory, and stress-resistance endpoints.
- Primary mechanism — MC4R (melanocortin-4 receptor — a brain receptor involved in learning and mood) activation triggering cAMP/PKA and MAPK/ERK cascades, rapid BDNF / NGF / GDNF gene induction, and monoamine-system activation (dopamine and serotonin).
- Community intranasal dose in Flow State — 300–600 mcg per day, split across nostrils. Daily dosing for 2–3 week cycles is the most-reported pattern; users often run it in tandem with Selank.
- Half-life — Short intranasal plasma half-life, but central BDNF effects outlast plasma clearance.
AEDG · Pineal Tetrapeptide
- What it is — Ala-Glu-Asp-Gly, a four-amino-acid synthetic peptide from the Khavinson pineal-bioregulator program (a Russian / Soviet research lineage that identified short peptides from organ extracts as regulatory signals). The most-discussed longevity peptide in community circulation.
- Documented effects — In-vitro telomerase activation (Khavinson 2003; PMID 12937682, replicated Al-Dulaimi 2025; PMID 40908429), mouse lifespan and tumor-incidence modulation, and sleep-quality / sleep-architecture improvements in older adults in open-label cohorts.
- Primary mechanism — Proposed to activate telomerase and ALT (alternative lengthening of telomeres — the second pathway cells use to maintain chromosome caps) pathways; also proposed to bind DNA sequences and modulate gene expression in the pineal gland and beyond. Mechanism remains partly characterized.
- Community dose in Flow State — 5–10 mg per administration, cycled (not daily long-term) — commonly 10–20 day SubQ or intranasal courses, one to three times per year. Epitalon is the compound that does NOT run daily alongside Selank and Semax.
- Half-life — Short plasma half-life; the proposed mechanism (transcriptional modulation) produces effects that outlast plasma clearance.
Why People Use It
Flow State arrived in Western community circulation roughly 2022–2024, as peptide discourse on X matured and biohacker audiences that had cycled through the GLP-1 (a gut hormone class — the Ozempic / Wegovy lineage) and nootropic waves started looking for the next edge. The unifying pitch: three Russian peptides that each do something different, stacked as a daily cognitive-plus-sleep protocol.
The framing that made it travel was “focus, calm under load, and sleep architecture.” Each phrase maps to one of the three components. Selank delivers the calm — anxiolytic without the sedation of a benzodiazepine. Semax delivers the focus — BDNF-driven cognitive engagement without the tolerance issues of classical stimulants. Epitalon delivers the sleep angle — pineal-peptide modulation of sleep quality and, in Khavinson-group data, sleep architecture in older cohorts. Three layers, three non-overlapping mechanisms, one branded bundle.
On paper the mechanism stack is clean. Tuftsin-family peptide (Selank) does not share a primary receptor with an ACTH-derived heptapeptide (Semax), and neither shares signaling with a pineal tetrapeptide (Epitalon). Users see this as an argument for safe stacking. The argument is mechanistically reasonable; it is not the same thing as empirical evidence of combination safety.
The community that runs it tends to be the overlap of the Russian-peptide enthusiast subculture and the biohacker audience that has already cycled through Semax or Selank individually. “Flow State” is what happens when each of those three compounds has its own audience and someone packages all three together. The name is marketing; the compounds are not.
What the Research Actually Shows
The individual compounds have real research. The combination does not. Read the evidence layer by layer.
- Selank — clinical anxiety data — Zozulia et al. 2008 (PMID 18454096): 62 patients with generalized anxiety disorder and neurasthenia, Selank vs medazepam; similar anxiolytic effect plus additional antiasthenic benefit. Basis for the 2009 Russian registration.
- Selank — BDNF and GABAergic mechanism — Volkova et al. 2016 (PMC4757669): GABAergic gene-expression modulation in brain tissue and cell models. Inozemtseva et al. 2019 (PMID 31625062): BDNF elevation in rat hippocampus and prefrontal cortex, protecting against ethanol-induced memory impairment.
- Semax — ischemic stroke clinical data — Gusev and Skvortsova 1997 (PMID 11517472): 30 acute hemispheric ischemic stroke patients, improved neurological-recovery endpoints in adjunctive use. Basis for the 1994 Russian registration and subsequent expansion.
- Semax — BDNF / neurotrophin mechanism — Dolotov et al. 2006 (PMID 16635254): intranasal Semax elevated BDNF in rat basal forebrain within three hours at 50–250 μg/kg. Volkova et al. 2006 (PMID 16996037): hippocampal BDNF and TrkB (BDNF's receptor — how brain growth signals reach neurons) regulation.
- Epitalon — telomerase activation — Khavinson, Bondarev, Butyugov 2003 (PMID 12937682): telomerase activation and telomere elongation in human somatic cells in culture. The paper that launched modern community interest. Al-Dulaimi et al. 2025 (PMID 40908429): independent Western-lab replication showing telomerase upregulation and ALT-pathway activation in human cell lines.
- Epitalon — longevity / mortality cohort — Khavinson and Morozov 2003 (PMID 14523363): 266 patients over age 60, 6–8 year follow-up, Epithalamin reduced 6-year mortality 1.6–1.8× vs control, 2.5× combined with thymalin, 4.1× with annual re-administration. Prospective cohort rather than RCT; methodologically heterogeneous; has not been replicated at Western Phase 3 standard.
- The combination — zero published research — No RCT, no case series, no published combined pharmacokinetics or pharmacodynamics. Every “Flow State” synergy claim is speculative extrapolation from single-compound studies to a three-way combination that has never been tested as a unit.
Honest Evidence Framing
Selank has one 62-patient pivotal Russian trial. Semax has Russian regulatory approval based on small-to-moderate trials plus decades of clinical use. Epitalon has in-vitro mechanism data, animal lifespan data, and a long-duration elderly-mortality cohort that has never been replicated at Western Phase 3 standard. These are three reasonable single-compound evidence bases. They do not constitute evidence for the combination. The three compounds have never been tested together in a published trial.
Safety & Caveats
- Individual compound safety — Selank, Semax, and Epitalon each have reasonable Russian clinical safety profiles across their documented indications. None has a Western Phase 3 safety database.
- Combination safety — Unknown. No published combination trial. No combined pharmacokinetic profile. No combined long-term follow-up data.
- Intranasal administration — Selank and Semax are dosed intranasally, which bypasses hepatic first-pass metabolism (the liver's first crack at degrading a dose before it reaches circulation). This improves central availability but also makes dose reproducibility more technique-dependent than subcutaneous injection.
- Receptor cross-talk in vivo — Mechanisms don't overlap on paper (tuftsin-family, ACTH-derived, pineal tetrapeptide). In-vivo receptor cross-talk across BDNF, MC4R, GABA, and pineal signaling systems is not characterized for the combination.
- Cycling — Epitalon is the one compound that most community protocols do NOT run daily long-term; short courses (10–20 days, one to three times per year) are the common pattern. Selank and Semax are more commonly run daily for 2–3 week cycles. Mixing the cadences is where user error most often enters.
- Long-term safety data for the combination — Does not exist. Decades of individual Russian clinical use are not decades of combination use.
- Source quality — Research-peptide vendor quality varies. Third-party HPLC plus mass-spec certificates of analysis are the minimum bar for each of the three components.
- Pregnancy / lactation — Not studied for any of the three. Contraindicated by default.
- Active or recent malignancy — Epitalon's proposed telomerase-activation mechanism is the most relevant caution here. Telomerase activation is not inherently oncogenic, but it is the same axis cancer cells exploit. Avoid in active malignancy until more is known.
Kalios’s Verdict
Verdict
Selank, Semax, and Epitalon each have real individual research supporting their respective uses. The “Flow State” combination itself has no published research and no regulatory status as a combination product. Users of this stack are extrapolating from single-compound data to a three-way combination that has never been tested as a unit.
Kalios does not endorse or recommend the Flow State stack. If you are using this combination, you are extrapolating. Proceed with appropriate skepticism about the marketing framing, read the individual compound profiles rather than the stack pitch, and consult a healthcare provider who actually understands these compounds. The three components are interesting; the branded bundle is a community-assembled product, not a validated protocol.
Related Compounds
People researching the Flow State stack often also look at these:
The calm leg. Russian-approved anxiolytic peptide with anxiolytic and mild nootropic profiles. Tuftsin-family, GABAergic, and BDNF-modulating.
The focus leg. ACTH-derived heptapeptide with Russian registration for acute ischemic stroke. Rapid BDNF induction and monoamine activation.
The sleep / longevity leg. Khavinson pineal tetrapeptide with telomerase-activation mechanism data and long-duration elderly mortality cohort.
Different axis, different goal. CJC-1295 plus Ipamorelin for pulsatile growth hormone release — the recovery / body-composition side of community peptide use.
The anti-inflammatory longevity stack — GHK-Cu plus BPC-157 plus TB-500 plus KPV. Different compounds, different use case, same “stack of four” philosophy.
Key References
No clinical trial has studied the Selank + Semax + Epitalon combination in humans. The references below are for the individual components and their mechanistic framework.
- Zozulia AA, Neznamov GG, Syunyakov TS, et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096. (Russian Phase 3 pivotal trial vs medazepam.)
- Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. PMID: 26903861. PMC4757669.
- Inozemtseva LS, Kudryavtseva NN, Bobkova NV, et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bull Exp Biol Med. 2019;167(6):776-779. PMID: 31625062.
- Gusev EI, Skvortsova VI, Miasoedov NF, et al. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PMID: 11517472.
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82-86. PMID: 16635254.
- Volkova MV, Shadrina MI, Kolomin TA, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PMID: 16996037.
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682.
- Al-Dulaimi MS, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. 2025. PMID: 40908429. PMC12411320.
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363.
- Kost NV, Sokolov OY, Gabaeva MV, et al. [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]. Bioorg Khim. 2001;27(3):180-183. PMID: 11443939.
Last updated: April 2026 | Profile authored by Kalios Peptides research team